{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:14:45Z","timestamp":1777774485980,"version":"3.51.4"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001259","name":"National Kidney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002538"],"award-info":[{"award-number":["UL1TR002538"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n In randomized trials, the primary analysis often estimates the average treatment effect on a clinical endpoint. Some treatments also lead to early changes in a biomarker that is prognostic for the clinical endpoint, prompting investigators to explore how these acute biomarker changes might inform the treatment\u2019s effect on long-term clinical outcomes. A naive analysis that directly examines treatment-by-biomarker-change interactions may lead to biased estimates because it fails to account for the fact that biomarker changes are influenced by the treatment and post-randomization factors. A key statistical challenge is that we do not know whether the observed biomarker change in an individual patient truly reflects a treatment-induced effect or whether the change would have occurred under placebo as well. This uncertainty makes it difficult to disentangle the causal effect of the treatment from natural biomarker variability. We apply principal stratification with a normal copula governed by the correlation\n \n \n \n \n \n \u03c1<\/mml:mi>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n between the potential acute biomarker changes under treatment and placebo. A flexible model for the conditional distribution of the clinical endpoint given the biomarker change enables estimation of the conditional average treatment effect on the clinical endpoint, given the acute biomarker change under treatment, as a function of\n \n \n \n \n \n \u03c1<\/mml:mi>\n <\/mml:mrow>\n <\/mml:math>\n <\/jats:alternatives>\n <\/jats:inline-formula>\n . We illustrate the method by determining how knowledge of acute change in estimated glomerular filtration rate modifies the expected effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on clinical endpoints in patients with chronic kidney disease.\n <\/jats:p>","DOI":"10.1371\/journal.pone.0347741","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:46:11Z","timestamp":1777484771000},"page":"e0347741","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implications of acute change in estimated Glomerular Filtration Rate (eGFR) for the effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on long-term endpoints"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6883-6822","authenticated-orcid":true,"given":"Ransmond O.","family":"Berchie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"8","key":"pone.0347741.ref001","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"O Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"pone.0347741.ref002","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"BL Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"pone.0347741.ref003","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"HJ Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0347741.ref004","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"V Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0347741.ref005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"C Wanner","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0347741.ref006","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"HJL Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"pone.0347741.ref007","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/dom.12654","article-title":"Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers","volume":"18","author":"HJL Heerspink","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"pone.0347741.ref008","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.34067\/KID.0001172021","article-title":"eGFR Decline after SGLT2 Inhibitor Initiation: the Tortoise and the Hare Reimagined","volume":"2","author":"AY Meraz-Mu\u00f1oz","year":"2021","journal-title":"Kidney360"},{"issue":"4","key":"pone.0347741.ref009","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.kint.2020.10.042","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","volume":"99","author":"M Oshima","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"pone.0347741.ref010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.kint.2020.10.031","article-title":"Characterization and implications of the initial estimated glomerular filtration rate \u201cdip\u201d upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial","volume":"99","author":"BJ Kraus","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"pone.0347741.ref011","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.0006-341X.2002.00021.x","article-title":"Principal stratification in causal inference","volume":"58","author":"CE Frangakis","year":"2002","journal-title":"Biometrics"},{"issue":"4","key":"pone.0347741.ref012","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1080\/19466315.2023.2166097","article-title":"Assessing the commonly used assumptions in estimating the principal causal effect in clinical trials","volume":"15","author":"Y Qu","year":"2023","journal-title":"Statistics in Biopharmaceutical Research"},{"issue":"5","key":"pone.0347741.ref013","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1467-9868.2006.00568.x","article-title":"Bounds on causal effects in three-arm trials with non-compliance","volume":"68","author":"J Cheng","year":"2006","journal-title":"Journal of the Royal Statistical Society Series B: Statistical Methodology"},{"issue":"2","key":"pone.0347741.ref014","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.spl.2007.05.015","article-title":"Sharp bounds on the causal effects in randomized experiments with \u201ctruncation-by-death\u201d","volume":"78","author":"K Imai","year":"2008","journal-title":"Statistics & Probability Letters"},{"issue":"496","key":"pone.0347741.ref015","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1198\/jasa.2011.tm10265","article-title":"Identifiability and estimation of causal effects by principal stratification with outcomes truncated by death","volume":"106","author":"P Ding","year":"2011","journal-title":"Journal of the American Statistical Association"},{"issue":"5","key":"pone.0347741.ref016","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1467-9868.2011.00780.x","article-title":"Augmented designs to assess principal strata direct effects","volume":"73","author":"A Mattei","year":"2011","journal-title":"Journal of the Royal Statistical Society Series B: Statistical Methodology"},{"issue":"503","key":"pone.0347741.ref017","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1080\/01621459.2013.802238","article-title":"Using secondary outcomes to sharpen inference in randomized experiments with noncompliance","volume":"108","author":"F Mealli","year":"2013","journal-title":"Journal of the American Statistical Association"},{"issue":"5","key":"pone.0347741.ref018","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3102\/1076998616646199","article-title":"Identification of principal causal effects using additional outcomes in concentration graphs","volume":"41","author":"F Mealli","year":"2016","journal-title":"Journal of Educational and Behavioral Statistics"},{"issue":"4","key":"pone.0347741.ref019","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/rssb.12135","article-title":"Principal causal effect identification and surrogate end point evaluation by multiple trials","volume":"78","author":"Z Jiang","year":"2015","journal-title":"Journal of the Royal Statistical Society Series B: Statistical Methodology"},{"issue":"3","key":"pone.0347741.ref020","doi-asserted-by":"crossref","DOI":"10.1214\/24-BA1425","article-title":"Assessing causal effects in the presence of treatment switching through principal stratification","volume":"20","author":"A Mattei","year":"2025","journal-title":"Bayesian Anal"},{"issue":"2","key":"pone.0347741.ref021","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1541-0420.2008.01108.x","article-title":"Sensitivity analysis for principal stratum direct effects, with an application to a study of physical activity and coronary heart disease","volume":"65","author":"A Sj\u00f6lander","year":"2009","journal-title":"Biometrics"},{"issue":"4","key":"pone.0347741.ref022","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/rssb.12538","article-title":"Multiply robust estimation of causal effects under principal ignorability","volume":"84","author":"Z Jiang","year":"2022","journal-title":"Journal of the Royal Statistical Society Series B: Statistical Methodology"},{"issue":"2","key":"pone.0347741.ref023","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/biostatistics\/kxt051","article-title":"Surrogacy assessment using principal stratification when surrogate and outcome measures are multivariate normal","volume":"15","author":"ASC Conlon","year":"2014","journal-title":"Biostatistics"},{"key":"pone.0347741.ref024","unstructured":"Lu S, Jiang Z, Ding P. Principal stratification with continuous post-treatment variables: nonparametric identification and semiparametric estimation. In: 2024. https:\/\/arxiv.org\/abs\/2309.12425"},{"issue":"496","key":"pone.0347741.ref025","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1198\/jasa.2011.ap10425","article-title":"A Bayesian semiparametric approach to intermediate variables in causal inference","volume":"106","author":"L Schwartz","year":"2011","journal-title":"Journal of the American Statistical Association"},{"key":"pone.0347741.ref026","unstructured":"Antonelli J, Mealli F, Beck B, Mattei A. Principal stratification with continuous treatments and continuous post-treatment variables. 2023. https:\/\/arxiv.org\/abs\/2309.14486"},{"key":"pone.0347741.ref027","unstructured":"Zorzetto D, Canale A, Mealli F, Dominici F, Bargagli-Stoffi FJ. Bayesian nonparametrics for principal stratification with continuous post-treatment variables. 2024. https:\/\/arxiv.org\/abs\/2405.17669"},{"key":"pone.0347741.ref028","volume-title":"An Introduction to Copulas","author":"RB Nelsen","year":"2006","edition":"2"},{"issue":"494","key":"pone.0347741.ref029","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1198\/jasa.2011.ap09094","article-title":"Modeling partial compliance through copulas in a principal stratification framework","volume":"106","author":"F Bartolucci","year":"2011","journal-title":"Journal of the American Statistical Association"},{"issue":"4","key":"pone.0347741.ref030","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1541-0420.2012.01781.x","article-title":"Bayesian inference for the causal effect of mediation","volume":"68","author":"MJ Daniels","year":"2012","journal-title":"Biometrics"},{"issue":"4","key":"pone.0347741.ref031","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/biom.12883","article-title":"Using survival information in truncation by death problems without the monotonicity assumption","volume":"74","author":"F Yang","year":"2018","journal-title":"Biometrics"},{"key":"pone.0347741.ref032","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/biomet\/36.1-2.149","article-title":"Systems of frequency curves generated by methods of translation","volume":"36","author":"NL Johnson","year":"1949","journal-title":"Biometrika"},{"issue":"1","key":"pone.0347741.ref033","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"LA Inker","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"pone.0347741.ref034","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3437-9","volume-title":"Sequential Monte Carlo methods in practice","author":"A Doucet","year":"2001"},{"issue":"446","key":"pone.0347741.ref035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"JP Fine","year":"1999","journal-title":"Journal of the American Statistical Association"},{"key":"pone.0347741.ref036","first-page":"216","article-title":"Contribution to the discussion of paper by D. R. Cox","volume":"34","author":"NE Breslow","year":"1972","journal-title":"Journal of the Royal Statistical Society: Series B"},{"issue":"24","key":"pone.0347741.ref037","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"V Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0347741.ref038","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1002\/sim.5815","article-title":"Goodness-of-fit test for proportional subdistribution hazards model","volume":"32","author":"B Zhou","year":"2013","journal-title":"Stat Med"},{"issue":"7","key":"pone.0347741.ref039","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"B Neal","year":"2017","journal-title":"N Engl J Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:46:20Z","timestamp":1777484780000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0347741"}},"subtitle":[],"editor":[{"given":"Nestor","family":"Oliva Damaso","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0347741","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]}}}